JP#WUXI RC2609B(68014.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
JP#WUXI RC2609B
68014.HK
News
View More

WuXi Biologicsand Sinorda Biomedicine partner to develop SND006, a bispecific antibody.

On January 28, 2026, in Shanghai, WuXi Biologics (stock symbol:, a prominent international Contract Research, Development, and Manufacturing Organization (CRDMO), partnered with Sinorda Biomedicine to collaboratively work on SND006, a groundbreaking drug. This strategic alliance aims to combine resources for the development and production of SND006, marking a significant step in the pharmaceutical industry.

Unusual Whales·
US
WXXWY
-1.83%
HK
02269
-1.04%
Unusual Whales·
US
WXXWY
-1.83%
HK
02269
-1.04%

WuXi Biologics and Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics has partnered with Sinorda Biomedicine to develop SND006, a bispecific antibody for autoimmune diseases. The collaboration will leverage WuXi's manufacturing expertise to expedite preclinical studies and the IND application process in China and the U.S. This partnership aims to address unmet medical needs in autoimmune diseases and may extend to other projects in Sinorda's pipeline.

Reuters·
HK
02269
-1.04%
US
WXXWY
-1.83%
Reuters·
HK
02269
-1.04%
US
WXXWY
-1.83%

02:00 ET HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HanchorBio, Inc. has entered a strategic partnership with WuXi Biologics to advance its next-generation bi- and multi-functional fusion protein pipeline. The collaboration will leverage WuXi's end-to-end biologics development and manufacturing services to enhance clinical translation and manufacturing efficiency. This partnership aims to accelerate the development of HanchorBio's innovative fusion proteins, supporting its proprietary Fc-Based Designer Biologics (FBDB™) platform. Both companies emphasize the importance of execution speed and scalability in bringing transformative therapies to patients worldwide.

prnewswire·
US
WXXWY
-1.83%
HK
02269
-1.04%
prnewswire·
US
WXXWY
-1.83%
HK
02269
-1.04%

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

HK Stock Movers Tracker·
HK
03696
+9.72%
HK
02228
+0.64%
HK
02269
-1.04%
HK Stock Movers Tracker·
HK
03696
+9.72%
HK
02228
+0.64%
HK
02269
-1.04%

Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows

Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows

marketscreener·
HK
02269
-1.04%
marketscreener·
HK
02269
-1.04%
Posts
View More
© 2026 Longbridge｜Disclaimer